Table 3. Initial β-lactam treatment and 28-days mortality comparison between study groups.
| β-lactams | β-lactam monotherapy n = 202 | SGA-group1 n = 197 | β -Lactam monotherapy vs SGA groups | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Unadjusted | Adjusted2 | ||||||||
| n | Mortality3 (%) | n | Mortality3 (%) | HR (95% CI) | p | HR (95% CI) | p | ||
| Broad-spectrum β-lactams | Total | 77 | 20 (26) | 30 | 1 (3) | 8.6 (1.1–64.2) | 0.036 | 10.2 (1.3–76.9 | 0.024 |
| Ceftazidime | 6 | 2 | |||||||
| Imipenem/cilastatin | 16 | 7 | |||||||
| Meropenem | 6 | 1 | |||||||
| Piperacillin/tazobactam | 49 | 12 (24) | 20 | 0 (0) | n/a4 | 0.014 | n/a4 | ||
| Other β-lactams | Total | 125 | 25 (20) | 167 | 167 (11) | 1.8 (1.0–3.3) | 0.045 | 3.5 (1.8–6.8) | <0.001 |
| Benzylpenicillin | 20 | 3 (15) | 60 | 3 (5) | 3.3 (0.7–16.3) | 0.15 | 29.4 (2.6–335) | 0.006 | |
| Cefotaxime | 94 | 19 (20) | 105 | 16 (15) | 1.3 (0.7–2.6) | 0.38 | 2.2 (1.0–4.6) | 0.038 | |
| Cefuroxime | 5 | 1 | |||||||
| Cloxacillin | 6 | 1 | |||||||
1 SGA in combination with a β-lactam antibiotic.
2 Adjusted for age, Charlson comorbidity score, SOFA-score and NEWS2-score as continuous variables and sex and immunosuppression as categorical variables.
3 28-days mortality in number and percentage.
4 Not applicable due to no mortality cases in the SGA-group.